Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Tourette Deep Brain Stimulation (DBS) Target Detection & Suppression

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05371041
Recruitment Status : Recruiting
First Posted : May 12, 2022
Last Update Posted : June 30, 2022
Sponsor:
Collaborator:
National Institute of Neurological Disorders and Stroke (NINDS)
Information provided by (Responsible Party):
University of Florida

Brief Summary:
The investigators will implant and monitor 8 research subjects with a subcortical closed-loop system for detection and suppression of tics. The project will use the FDA-approved "Medtronic Percept PC" device, which is an implantable neurostimulator capable of recording neural signals. The study will target the CM nucleus of the thalamus and the aGPi in each brain hemisphere from each subject and we will connect the two leads placed in each brain hemisphere to two Percept devices.

Condition or disease Intervention/treatment Phase
Tourette Syndrome Device: Medtronic Percept Neurostimulator Not Applicable

Detailed Description:

Tourette syndrome (TS) is a continuous lifelong disabling condition that is highly prevalent and socially embarrassing.

DBS has emerged as a promising treatment option for addressing uncontrollable tics in medically resistant and severe cases of TS frequently involving self-injurious behavior. The investigators have undertaken a major informatics initiative by establishing the International TS DBS Registry and Database, a multi-country consortium that has captured long term outcomes of 277 TS DBS patients representing 50-75% of the worldwide population. From these outcomes, two deep brain targets have emerged as potentially effective: the centromedian nucleus region (CM) of the thalamus, and the anterior globus pallidus internus (aGPi). However, the current understanding of tic generation is limited by many factors including a lack of animal models for TS, normal brain structure as revealed by structural imaging, and the impracticality of studying involuntary motor tics with functional imaging. Next generation closed-loop DBS systems can record brain activity in patients with TS and identify the neurophysiological correlates of tics. Moreover, these devices can deliver stimulation in response to a patient's symptomatic state. Our overall goal is to develop neurophysiology driven and connectivity-guided closed-loop DBS systems for the improved treatment of TS.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 8 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Device Feasibility
Official Title: Defining Targets for Tic Detection and Suppression in Tourette Syndrome Deep Brain Stimulation
Actual Study Start Date : June 20, 2022
Estimated Primary Completion Date : August 31, 2026
Estimated Study Completion Date : August 31, 2026

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Medtronic Percept Neurostimulator
This is a deep brain stimulator that can also record brain signals and deliver stimulation through a control algorithm based on brain activity.
Device: Medtronic Percept Neurostimulator
This is a deep brain stimulator that can also record brain signals and deliver stimulation through a control algorithm based on brain activity.




Primary Outcome Measures :
  1. Yale Global Tic Severity Scale_(YGTSS) - Total Tic Score [ Time Frame: 6 months ]
    The YGTSS is a clinician-rated scale used to assess tic severity over the prior week. It includes a checklist of motor and vocal tics followed by an assessment of the number, frequency, intensity, complexity, and inference of motor tics and phonic tics - scored separately. Each of these dimensions is scored on a 0 to 5 scale. The YGTSS provides three tic severity scores: Total Motor (0 to 25); Total Phonic (0 to 25) and the combined Total Tic Severity Score (0 to 50), as well as a separate Impairment dimension scored from 0 to 50. The Total Tic Score (YGTSS-TTS) was used in these analyses.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • The diagnosis of TS must be made by both a fellowship-trained movement disorders neurologist and a psychiatrist and must meet Diagnostic and Statistical Manual of Mental Disorders (DSM-V) criteria for a diagnosis of TS.
  • Yale Global Tic Severity Scale (YGTSS; 100) must be >35/50 and the motor tic subscore >15. The TS must be causing incapacitation with severe distress, self-injurious behavior, and/or quality of life disruption. Obsessive Compulsive Disorder (OCD), Depression, and Attention Deficit Hyperactivity Disorder (ADHD) are not exclusionary4-6 provided tics are the major difficulty requiring surgical intervention.
  • There are no gender criteria for this study.
  • The subject's TS symptoms must be medication refractory. To meet the medication refractory criteria, subjects must have been treated by a psychiatrist or neurologist experienced in TS with therapeutic doses (doses adapted from Scahill's recommendations of at least three dopamine blocking drugs5) either 1-4 mg/day of haloperidol, 2-8 mg/day of pimozide, risperidone (1-3 mg/day), or aripiprazole (2.5-5 mg/day)]. There must be at a minimum7 single trial with an alpha-2 adrenergic agonist (0.1-0.3 mg/day).
  • Clinically relevant depression if present must be pharmacologically treated and deemed stable (by the study psychiatrist).
  • Must have been stabilized for one month on TS medication without a dose change prior to surgical intervention. If medication trials resulted in discontinuation of TS medications, the subject must be stabilized for three months off TS medicines.
  • Must be willing to keep TS related medications stable and unchanged throughout the trial.
  • Must have been offered habit reversal therapy/cognitive behavioral intervention therapy (HRT) if a subject did not have it prior to enrollment. Subjects are not required to participate in HRT but it will be highly encouraged, and must be completed prior to the start of the protocol. Those who improve significantly with HRT will be excluded from receiving surgery.
  • If the tic is focal or addressable by botulinum toxin treatment, the study neurologist will offer to administer a trial of botulinum toxin prior to consideration of surgical therapy. If the subject chooses not to have the treatment, they cannot participate in the study. If the subject responds satisfactorily to botulinum toxin, and their quality of life significantly improves, they will be excluded.
  • Must be 18 years of age or older

Exclusion Criteria:

  • Any previous neurosurgical intervention including DBS or ablative brain lesions, any metal in the head and any type of implanted stimulator.
  • Untreated or unstable anxiety, depression, bipolar disorder or other Axis I psychiatric disorder.
  • Presence of psychotic features.
  • Significant psychosocial factors that may impart an increased risk.
  • The presence of only simple motor tics, a movement disorder other than TS, or medication related movement disorders from TS medications.
  • The presence of drug-induced tics (potentially associated with the use of stimulant medications, anticonvulsant drugs, etc).
  • Severe medical co-morbidity including cardiovascular disorder, lung disorder, kidney disease, chronic neurological disease, hematological disease, or frailty that impact tolerability of the surgery as judged by the screening physicians.
  • Abnormal brain magnetic resonance imaging (MRI) scan including hydrocephalus, stroke, structural lesions, demyelinating lesions, or infectious lesions that would potentially confound the outcome or safety of the surgery as judged by the study neurosurgeon. Also excluded if severe atrophy is present on the brain scan.
  • Dementia or cognitive dysfunction that will place the subject at risk for worsening cognition, and/or may impact the ability to cooperate with tasks involved in the study.
  • Any attempt or intent of suicide in the last six months.
  • Significant substance abuse or dependence (e.g., stimulants, alcohol, opiates, benzodiazepines) within the past six months.
  • Multiple failed medication treatments of inadequate dose or duration.
  • History of noncompliance with previous medical and psychosocial treatment efforts.
  • Severe head banging tics (any tics which have the potential to result in damage to the DBS as judged by the neurosurgeon).
  • Women of child-bearing potential who are pregnant or who wish to become pregnant during the study (a urine pregnancy screen required).
  • History of multiple surgical procedures with poor outcomes.
  • Unexplained gaps in medical history.
  • Pending lawsuits or other legal action.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05371041


Locations
Layout table for location information
United States, Florida
Norman Fixel Institute for Neurological Diseases - University of Florida Recruiting
Gainesville, Florida, United States, 32608
Contact: Michael S Okun, M.D.    352-273-9892    okun@neurology.ufl.edu   
Sponsors and Collaborators
University of Florida
National Institute of Neurological Disorders and Stroke (NINDS)
Investigators
Layout table for investigator information
Principal Investigator: Michael Okun, MD University of Florida
Layout table for additonal information
Responsible Party: University of Florida
ClinicalTrials.gov Identifier: NCT05371041    
Other Study ID Numbers: IRB202102161
UH3NS119844 ( U.S. NIH Grant/Contract )
OCR41251 ( Other Identifier: UFOnCore )
First Posted: May 12, 2022    Key Record Dates
Last Update Posted: June 30, 2022
Last Verified: June 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Product Manufactured in and Exported from the U.S.: Yes
Additional relevant MeSH terms:
Layout table for MeSH terms
Tourette Syndrome
Syndrome
Disease
Pathologic Processes
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Tic Disorders
Movement Disorders
Heredodegenerative Disorders, Nervous System
Neurodegenerative Diseases
Genetic Diseases, Inborn
Neurodevelopmental Disorders
Mental Disorders